ubrogepant Treatment for Migraine Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine DUBLIN, March 11, 2019 /PRNewswire/ — Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for ubrogepant for the acute treatment of […]Continue Reading ...
Gormley P, Anttila V, Winsvold BS, Palta P, Esko T, Pers TH, Farh KH, Cuenca-Leon E, Muona M, Furlotte NA, Kurth T, Ingason A, McMahon G, Ligthart L, Terwindt GM, Kallela M, Freilinger TM, Ran C, Gordon SG, Stam AH, Steinberg S, Borck G, Koiranen M, Quaye L, Adams HH, Lehtimäki T, Sarin AP, Wedenoja […]Continue Reading ...
Home News Professional Meta-Analysis: Botulinum A Tops Placebo for Chronic Migraine MONDAY, Jan. 7, 2019 — For chronic migraine, botulinum type A injections are superior to placebo after three months of therapy, according to a meta-analysis published in the January issue of Plastic and Reconstructive Surgery. Eva Bruloy, M.D., from the University Hospital of Picardie […]Continue Reading ...
lasmiditan Treatment for Migraine Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine INDIANAPOLIS, Nov. 14, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute treatment […]Continue Reading ...
CHOP Researcher: Findings may suggest more effective headache treatments Pediatric researchers have discovered common gene variants associated with migraines in African-American children. The research adds to knowledge of genetic influences on childhood migraine and may lead to future precision medicine treatments for African-American children with these intense headaches. “Scientists already know that migraines may run […]Continue Reading ...
FDA Approves Emgality (galcanezumab-gnlm) for the Preventive Treatment of Migraine in Adults INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults.1 Emgality offers a once-monthly, self-administered, subcutaneous […]Continue Reading ...
FDA Approves Ajovy (fremanezumab-vfrm) for Preventive Treatment of Migraine September 14, 2018 — Today, the US Food and Drug Administration (FDA) approved Ajovy (fremanezumab-vfrm) for the preventive treatment of migraine in adults. Ajovy is the second FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related […]Continue Reading ...
August 14, 2018 Research published today reveals a potential mechanism for migraine causation which could explain why women get more migraines than men. The study, in Frontiers in Molecular Biosciences, suggests that sex hormones affect cells around the trigeminal nerve and connected blood vessels in the head, with estrogens — at their highest levels in […]Continue Reading ...
NICE has today (10 January) published draft guidance for public consultation which does not recommend erenumab (Aimovig, Novartis) for preventing migraine. The draft guidance looks at erenumab for preventing chronic and episodic migraine (as defined by the International Headache Society) in adults who have 4 episodes or more of migraine every month where at least […]Continue Reading ...
NEW HAVEN, Conn., Dec. 10, 2018 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced initial positive results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant, for the acute treatment of migraine. Based upon this interim analysis (database cutoff of November 21, 2018) of […]Continue Reading ...
Oct 23 2018 Novartis announced today that the full data from the LIBERTY study of Aimovig® (erenumab) in episodic migraine patients who had tried and failed two to four prior preventive treatments have been published in the Lancet. Patients treated with Aimovig had significant improvements on all primary and secondary endpoints of the study. Aimovig […]Continue Reading ...
By slightly changing the body’s own molecules using a small inhaler, certain migraine patients can either cut down on medication or do without it completely. This is shown by a pilot study which has been published in the scientific journal Cephalalgia. Patients who suffer from migraine with aura, which is where they experience either sensory […]Continue Reading ...
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVYTM (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults. AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for […]Continue Reading ...
To decrease the substantial health and economic burden of migraine on individuals and society, researchers need to examine and address how the disease differs between women and men, according to a report from the Society for Women’s Health Research published in the August issue of the Journal of Women’s Health. Women shoulder a significant amount […]Continue Reading ...
INDIANAPOLIS, June 27, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today results from a post-hoc analysis which demonstrated efficacy of Emgality™ (galcanezumab-gnlm) in patients with episodic and chronic migraine who had previously failed preventive treatment with Botox®* (onabotulinumtoxinA). Detailed results from a post-hoc analysis of three Phase 3 studies (EVOLVE-1, EVOLVE-2 and […]Continue Reading ...
- Hidden differences between pathology of CTE and Alzheimer’s disease discovered
- Knowing causative genes of osteoporosis may open door to more effective treatments
- Toilet-seat based cardiovascular monitoring system getting ready to begin commercialization
- New model for intensive care identifies factors that send ill patients to ICU
- Recommendations Issued for HSCT in Multiple Myeloma
- Deep brain stimulation provides sustained relief for severe depression
- “Statistical significance” may soon be a thing of past?
- Researchers track effects of epigenetic marks carried by sperm chromosomes
- AHA News: Family Adopts Three Children With Three Different Heart Conditions
- Research into opioid painkillers could provide clues for safer drug development
- Lung cancer survivor recounts her lifetime struggles
- Radial and femoral approach for PCI achieve similar results in terms of survival
- Study sheds light on the optimal timing of coronary angiography in NSTEMI patients
- Excess hormones could cause a condition that can lead to blindness in women, study finds
- Dramatic shifts in first-time opioid prescriptions bring hope, concern
- Antidepressant drugs may not work when neurons are out of shape
- TTUHSC El Paso to establish endowed chair in neurology through a major grant
- New device approved by FDA for treating patients with moderate-to-severe heart failure
- People with peripheral artery disease have lower Omega-3 Index, shows research
- Trigger warnings have minimal impact on how people respond to content, shows research